Further investigation revealed that miR‐223 promotes erlotinib resistance in NSCLC cell lines, primarily by downregulating FBXW7 expression, which subsequently results in increased NOTCH activity in these cells. This evidence concerns the gene FBXW7 and non-small cell lung carcinoma.